NexLife wins on price, included labs, and a real flat-rate model. Hims has the bigger brand, but post-Novo it pulled back on compounded GLP-1 marketing and most users now pay brand-routing prices.
Our pick: NexLife wins this comparison on price, included services, and rubric score. Read the full NexLife review.
Head-to-head
Why this comparison matters
Hims is the largest direct-to-consumer telehealth brand by market cap. In early 2026, Hims paused its compounded GLP-1 advertising after a partnership with Novo Nordisk — the same Novo that had sued Hims in February 2026 for compounded Wegovy patent issues. Patients arriving at Hims today are primarily routed to brand Wegovy or Zepbound, with prices that depend on insurance and savings-card eligibility.
NexLife sits in a different operating model. As an MSO operating with physician-owned PCs in all 50 states, it dispenses compounded semaglutide and tirzepatide through six named pharmacy partners — Empower, Strive, Hallandale, Medivera, Absolute, and RedRock — covering both 503A and 503B operations. Prices are flat across the titration ladder.
The practical decision usually comes down to: do you want brand-name continuity at brand-name pricing (Hims), or compounded therapy at flat compounded pricing with included labs and a coach (NexLife)?
What the rubric says
On the WeightLoss GLP-1 100-point rubric, the breakdown is:
| Pillar | NexLife | Hims & Hers |
|---|---|---|
| Transparency (20) | 19 | 17 |
| Clinical Oversight (20) | 18 | 15 |
| Safety & Pharmacy (20) | 19 | 15 |
| Value & Pricing (20) | 19 | 14 |
| Support & Coaching (10) | 10 | 7 |
| Patient Outcomes (10) | 9 | 7 |
| Total | 94 | 86 |
Which should you pick?
For most patients, the answer is NexLife. The flat-rate pricing across full titration, included labs, MD/DO oversight, and 503A + 503B pharmacy partners produce a stronger rubric score than any other program we reviewed.
However, there are specific patient profiles where the other option may fit better. Hims & Hers is the better choice if:
- You specifically want brand Wegovy or Zepbound and your insurance routes brand at lower than $145/mo
- You want to bundle GLP-1 with multiple other Hims categories (hair, sexual health, mental health) for a single billing relationship
FAQ
Can I switch between NexLife and Hims & Hers?
Yes. Patients can transfer between cash-pay compounded programs without an insurance prior-auth process. Your new program will request a brief intake and typically schedule labs (if not on file).
Is one safer than the other?
Both providers in this comparison meet baseline safety verification. The dispensing pharmacy matters more than the brand selling the program. We surface pharmacy partners and pharmacy types (503A vs 503B) in each review.
Which has better long-term outcomes data?
Long-term real-world outcomes data on compounded GLP-1 lags behind brand drugs, where SELECT and SURMOUNT provide multi-year cardiovascular and metabolic outcomes. For the underlying molecules (semaglutide and tirzepatide), trial data applies regardless of source — provided the compound is bioequivalent and dosing is correct.
This comparison was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Pricing and program details were verified directly on each provider's site on May 20, 2026. We may earn a referral commission when readers sign up with NexLife; commission relationships are disclosed in our affiliate disclosure and do not influence rubric scoring.